

Cipla



AGM - MD & GCEO's Address

Umang Vohra

Aug 2020



Cipla launched a **helpline** for supporting patients with COVID products availability

Cipla

Over 72K calls and mails received so far..



FOR COVID PERIOD ONLY

Caring for life, 24x7

During the COVID-19 pandemic, **Cipla** has set up a **helpline** to share information on availability of critical Cipla products.

Please give us a call or email us

 **86573 11088**

NEW ADDITION **022-6282 0886**

info.availability@cipla.com

Cipremi <small>Remdesivir for Injection 100 mg/ vial (Lyophilized)</small>	Actemra <small>Tocilizumab</small>	Imulast <small>Hydroxychloroquine 200 & 400 mg Tabs</small>	Azee <small>Azithromycin</small>	Ciphands <small>Hand sanitization products</small>
--	--	---	--	--

Disclaimer: This is intended solely for patient support in helping to find availability of Covid-19 medicines. This is not a medicine dispensing or pharmacy service. Any advice regarding the management of any medical condition should only be sought from a consulting physician/doctor and medicines shall be made available only on doctor's prescription. No part of this may be reproduced, transmitted or stored in any form or by any means either mechanically or electronically without prior intimation.

Cipla has been at the forefront of the fight against COVID-19

Cipla

**Cipremi
(Remdesivir)**



**Actemra
(Tocilizumab)**



**Lopimune
(Lopi+Rito)**



**Ciplenza
(Favipiravir)**



**Ciphands
Expert**



**Cofsils Face
mask**



**Remdesivir launched
in South Africa**

Cipla to bring Covid-19 treatment remdesivir to SA

The manufacturer plans to sell the drug at around R5,600 for a five-day course

02 JULY 2020 - 19:46 by TAMAR KAHN

**Emergency Healthcare
Units for COVID testing**



**Supply of ARVs
despite lockdowns**



**NY interns at a
community service effort**




Satisfactory FY20 Performance despite COVID-19 related challenges & Goa remediation efforts **Cipla**



↑ 5%
y-o-y



↑ 2%
y-o-y



↑ 1%
y-o-y



Growth across key businesses

One India (Rx+Gx+CHL) ↑ 5% y-o-y

SA (private) ↑ 11% y-o-y

North America ↑ 12% y-o-y

EU ↑ 14% y-o-y

API ↑ 5% y-o-y

Org health indicators continued to sustain in FY20



Great Place to Work certified – second year in a row



43 regulatory audits conducted (including US FDA and MHRA) demonstrating operational excellence



Responsible Resource Consumption – 9.1% energy from renewable resources; More than 70% of wastewater generated recycled/reused



Continue building a strong growth pipeline for the future with 6.9% R&D investment



13 patents filed; 52 new products launched; 6 clinical trials registered

Significant milestones towards solidifying our position as a 'Lung Leader' globally

Cipla



Ranks #2 in the sale of inhalers globally (by volume)¹



With presence in 50+ countries, Respiratory contributes to over 22% of total revenues



First Gx FDA Approval for Albuterol Inhalation Aerosol



Completed Phase-3 Clinical study of Advair



First-of-its-kind patient-centric initiative aimed to create mass awareness on Asthma - Berok Zindagi

Key priorities for the coming months



Managing the **here and now** - *Safety, Seamless Supply chain, Minimising Wastage*



Compliance across all sites



Prioritizing **key launches**



Turning adversity into **opportunity** (going beyond the obvious)



Constantly building and honing **capability & talent**